Trial Profile

Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Diabetic Macular Edema.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RC28 E (Primary) ; Conbercept
Indications Diabetic macular oedema
Focus Therapeutic Use
Sponsors RemeGen

Most Recent Events

19 Aug 2025 According to the RemeGen media release, data from this study presented as an oral report at the Association for Research in Vision and Ophthalmology (ARVO) 2025, Annual Meeting, May 7, 2025.
30 Aug 2023 Status changed from recruiting to completed.
26 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com